

# Cervical Cancer Screening

Caitlyn M. Rerucha, MD, Carl R. Darnall Army Medical Center, Fort Hood, Texas  
Rebecca J. Caro, DO, Bassett Army Community Hospital, Fort Wainwright, Alaska  
Vernon L. Wheeler, MD, Carl R. Darnall Army Medical Center, Fort Hood, Texas

Screening in women has decreased the incidence and mortality of cervical cancer. Precancerous cervical lesions (cervical intraepithelial neoplasias) and cervical carcinomas are strongly associated with sexually-transmitted high-risk human papillomavirus (HPV) infection, which causes more than 99% of cervical cancers. Screening methods include cytology (Papanicolaou test) and HPV testing, alone or in combination. The American Academy of Family Physicians and the U.S. Preventive Services Task Force recommend starting screening in immunocompetent, asymptomatic women at 21 years of age. Women 21 to 29 years of age should be screened every three years with cytology alone. Women 30 to 65 years of age should be screened every five years with cytology plus HPV testing or every three years with cytology alone. Screening is not recommended for women younger than 21 years or in women older than 65 years with an adequate history of negative screening results. The U.S. Preventive Services Task Force is in the process of updating its guidelines. In 2015, the American Society for Colposcopy and Cervical Pathology and the Society of Gynecologic Oncology published interim guidance for the use of primary HPV testing. (*Am Fam Physician*. 2018;97(7):441-448. Copyright © 2018 American Academy of Family Physicians.)



Illustration by Jennifer Fairman

**Cervical cancer** is responsible for more than 7% of all cancer-related deaths in women worldwide.<sup>1</sup> Most cases of cervical cancer (85%) occur in developing countries that have ineffective screening programs.<sup>2</sup> Total cancer-related deaths in American women declined by more than 80% from 1930 to 2012, primarily because of widespread use of cytology (Papanicolaou [Pap] test).<sup>3</sup> The annual incidence and mortality rate of cervical cancer have decreased nearly 50% since 1975; there were reportedly 7.5 cases per 100,000

women from 2009 to 2013, and 2.3 deaths per 100,000 women in 2011.<sup>4,5</sup> The most common types of cervical cancer are squamous cell carcinoma and adenocarcinoma.<sup>2</sup> The American Cancer Society projected that there would be 12,820 new cases of cervical cancer diagnosed in 2017 in the United States, with 4,210 deaths.<sup>3</sup>

Nearly one-half of women with cervical cancer were not screened before diagnosis, and another 10% were not screened within the previous five years.<sup>4</sup> Although the rates of cervical cancer in U.S. women who have adequate access to screening are decreasing, patients who lack regular preventive health care services continue to be at higher risk.<sup>6</sup>

Types of human papillomavirus (HPV) are categorized as low risk (wart-causing) and high risk (oncogenic, cancer-causing). Precancerous cervical lesions, called cervical intraepithelial neoplasias (CINs), and cervical carcinomas are strongly associated with sexually transmitted

**See related** article on cervical cancer evaluation and management on page 449.

**CME** This clinical content conforms to AAFP criteria for continuing medical education (CME). See CME Quiz on page 439.

**Author disclosure:** No relevant financial affiliations.

**Patient information:** A handout on this topic is available at <https://familydoctor.org/condition/cervical-cancer/>.

**Recommendations from the Choosing Wisely Campaign**

Recommendation	Sponsoring organization
Do not perform annual cervical cytology (Pap test) or annual HPV screening in immunocompetent women with a history of negative screening.	American Society for Colposcopy and Cervical Pathology
Do not perform cervical cytology (Pap test) or HPV screening in immunocompetent women younger than 21 years.	American Society for Colposcopy and Cervical Pathology
Do not perform low-risk HPV testing.	American Society for Clinical Pathology
Do not perform cervical cytology (Pap test) in women younger than 21 years or in women after total hysterectomy for benign disease.	American Academy of Family Physicians
Do not perform screening for cervical cancer in low-risk women 65 years or older or for women who have had a total hysterectomy for benign disease.	American College of Preventive Medicine

HPV = human papillomavirus; Pap = Papanicolaou.

**Source:** For more information on the Choosing Wisely Campaign, see <http://www.choosingwisely.org>. For supporting citations and to search Choosing Wisely recommendations relevant to primary care, see <http://www.aafp.org/afp/recommendations/search.htm>.

**TABLE 1**

**Clinically Important HPV Genotypes**

Genotype	Pathogenesis	Commonly used FDA-approved HPV tests for genotype detection and specification*
<b>High risk (oncogenic)</b>		
Type 16	Causes 50% of all squamous cell carcinomas of the cervix and 55% to 60% of all cervical cancers worldwide	Pooled detection by Hybrid Capture II HPV DNA test, Cervista HPV DNA test, and Aptima HPV mRNA test Specific detection by Cobas HPV DNA test
Type 18	Causes 20% of cervical adenocarcinomas	Pooled detection by Hybrid Capture II HPV DNA test, Cervista HPV DNA test, and Aptima HPV mRNA test Specific detection by Cobas HPV DNA test
Other: types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, (66), 68	All types combined cause 25% of cervical cancers	Results are not differentiated by type and are reported as positive or negative for these 12 high-risk HPV strains Pooled detection of all types except for type 66 by Hybrid Capture II HPV DNA test Pooled detection of all 14 oncogenic types by Cervista HPV DNA test, Cobas HPV DNA test, and Aptima HPV mRNA test
<b>Low risk (wart-causing)</b>		
Types 6 and 11	Cause 90% to 95% of anogenital warts	Testing is not recommended

FDA = U.S. Food and Drug Administration; HPV = human papillomavirus.

\*—The Cobas HPV DNA test is currently the only test approved by the FDA for primary HPV screening.

Information from references 4, 8, and 9.

high-risk HPV infection, which causes more than 99% of cervical cancers.<sup>7</sup> There are more than 200 types of HPV strains, of which about 40 types commonly infect the anogenital region.<sup>8</sup> Types 16 and 18 are high-risk strains that cause 70% of all cervical cancers.<sup>8</sup> *Table 1* summarizes cervical cancer risk based on HPV genotype.<sup>4,8,9</sup> Risk factors for high-risk HPV infection include early onset of sexual activity, multiple sex partners, long-term use of oral contraceptives, low socioeconomic status, micronutrient deficiency, immunosuppression, and tobacco use.<sup>2</sup>

Most cervical HPV infections are transient, although a small percentage are persistent. It takes the immune system six to 24 months to clear a transient HPV infection.<sup>10</sup> Factors that determine which HPV infections will persist are not entirely understood, but infection with HPV type 16 or 18 is more likely to persist and progress. High-risk HPV infection is more likely to resolve in younger women. Other HPV-induced cancers include vaginal, vulvar, anal, penile, and oropharyngeal cancers.<sup>4</sup> It is unknown if previously resolved HPV infection produces immunity toward future infection with the same HPV genotype.

Screening with cytology can detect early cervical cancer precursors and early-stage disease. Precursors include atypical squamous

## SORT: KEY RECOMMENDATIONS FOR PRACTICE

cells of undetermined significance and low-grade squamous intraepithelial lesions on cytology, and mild dysplasia, also known as CIN1, on histology. Precancerous cervical lesions include high-grade squamous intraepithelial lesions and atypical glandular cells on cytology, and CIN2 and CIN3 (i.e., moderate and severe dysplasia) on histology.

### Cervical Cancer Screening Methods

Cervical cancer screening includes cytology and HPV testing, alone or in combination. Conventional cytology (a Pap test sample affixed to a slide at the time of testing) and liquid-based cytology (a newer method for collecting, transporting, and preparing cells collected by the Pap test in a liquid medium [e.g., ThinPrep Pap test]) provide comparable results. Both methods are acceptable and have nearly equivalent sensitivity and specificity for detection of high-grade CIN.<sup>4,11-14</sup>

HPV testing, alone or in combination with cytology, is more sensitive than cytology alone in detecting CIN2 and CIN3.<sup>15</sup> There are a variety of tests approved by the U.S. Food and Drug Administration (FDA) for detecting cervical HPV, including HPV DNA and HPV mRNA tests (*Table 1*<sup>4,8,9</sup>). Current methods for using cervical HPV testing in the United States include triage testing for patients with abnormal findings on cytology (reflex testing), adjunct testing with cytology (cotesting), and primary testing.

### Screening Recommendations

The decision of when, how, and how often to screen for cervical cancer depends on a woman's age, screening history, risk factors, and the choice of screening tests available. Current screening recommendations from the U.S. Preventive Services Task Force, the American Academy of Family Physicians, and other national organizations are summarized in *Table 2*<sup>4,15-21</sup> and *Table 3*.<sup>4,16,18-20,22</sup> Women with symptoms or visible cervical lesions on speculum examination should undergo diagnostic testing rather than screening.

Primary HPV testing was not previously recommended, largely because of concerns about low specificity and insufficient data to determine when positive HPV test results require diagnostic evaluation.<sup>4</sup> However, a large U.S. study

has since shown that primary HPV screening has equivalent or superior effectiveness to cytology alone.<sup>4,15,23</sup>

Additionally, an effective algorithm for managing patients with positive findings on primary HPV screening has been validated<sup>4,15,23</sup> (*Figure 1*<sup>15</sup>). As a result, the FDA approved the Cobas HPV DNA test in August 2014 for primary cervical cancer screening in women. In 2015, the American Society for Colposcopy and Cervical Pathology and the Society of Gynecologic Oncology provided interim guidance on the use of primary HPV testing<sup>4,15</sup> (*Table 2*).<sup>4,15-21</sup> The U.S. Preventive Services Task Force is currently reviewing the evidence regarding primary HPV testing.<sup>18</sup> The American Academy of Family Physicians suspended its Choosing Wisely recommendation against primary HPV testing in women younger than 30 years because of the uncertainty around the effectiveness of HPV testing alone.<sup>17</sup>

Although primary testing for high-risk HPV infection can be considered as an alternative to cytology-based screening methods, cytology alone or cotesting is recommended in major guidelines.<sup>4,14,15,17,18,20</sup>

Clinical recommendation	Evidence rating	References
Cervical cancer screening in women before 21 years of age leads to more harms than benefits and does not reduce cervical cancer incidence or mortality.	<b>A</b>	4, 14, 16, 18, 20
Average-risk women 21 to 29 years of age should be screened every three years with cytology alone.	<b>A</b>	4, 16, 18, 20
Average-risk women 30 to 65 years of age should be screened every three years with cytology alone or every five years with a combination of cytology and HPV testing.	<b>A</b>	4, 16, 18, 20
Cervical cancer screening should be discontinued in women older than 65 years with an adequate history of negative screening results.	<b>C</b>	4, 16, 18, 20
Annual cervical cancer screening is not recommended for average-risk women of any age.	<b>A</b>	4, 16, 18, 20
Women with a hysterectomy unrelated to cancer should not be screened for cervical cancer.	<b>C</b>	4, 16, 18, 20
Women with a hysterectomy related to a history of cancer should be screened for cervical cancer for 20 years after the hysterectomy.	<b>C</b>	4, 16, 18, 20
Primary HPV testing may be considered for cervical cancer screening every three years in women 25 years and older.	<b>B</b>	4, 15, 23

HPV = human papillomavirus.

**A** = consistent, good-quality patient-oriented evidence; **B** = inconsistent or limited-quality patient-oriented evidence; **C** = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <http://www.aafp.org/afpsort>.

TABLE 2

## Age-Based Cervical Cancer Screening Recommendations for Average-Risk Women

Patient age	Recommendations		
	ACS, ASCCP, and ASCP 2012 <sup>16</sup>	USPSTF and AAFP* 2012 <sup>17-19</sup>	ACP 2015 <sup>20</sup>
Younger than 21 years‡	Screening is not recommended	Screening is not recommended	Screening is not recommended
21 to 29 years	Cytology alone every three years	Cytology alone every three years HPV testing (alone or in combination with cytology) is not recommended in women younger than 30 years	Cytology alone every three years
30 to 65 years§	Cotesting every five years (preferred) Cytology alone every three years (acceptable) Primary HPV testing† is not recommended in most clinical settings	Cytology alone every three years is recommended For women who want to extend the screening interval, cotesting every five years is an option Primary HPV testing in women older than 30 years is not addressed	Cytology plus HPV testing every five years
Older than 65 years	Screening is not recommended in patients with an adequate history of negative screening results and no history of CIN2 or higher within the past 20 years	Screening is not recommended in women older than 65 years with an adequate history of negative screening results and who are not otherwise at high risk of cervical cancer	Screening is not recommended in women older than 65 years with an adequate history of negative screening results
Annual screening, all ages	Annual screening is not recommended	Annual screening is not recommended The annual well-woman visit can be used instead to discuss other health problems and preventive measures	Not addressed

**Note:** These guidelines should not be used for high-risk populations (see Table 3). Cotesting is defined as cytology (conventional or liquid-based) plus HPV DNA or mRNA testing.

AAFP = American Academy of Family Physicians; ACOG = American College of Obstetricians and Gynecologists; ACP = American College of Physicians; ACS = American Cancer Society; ASCCP = American Society for Colposcopy and Cervical Pathology; ASCP = American Society for Clinical Pathology; CIN = cervical intraepithelial neoplasia; HPV = human papillomavirus; SGO = Society of Gynecologic Oncology; USPSTF = U.S. Preventive Services Task Force.

\*—The USPSTF recommendations are currently being updated (see the draft statement at <https://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/cervical-cancer-screening2>). The AAFP recommendations are also under review.

†—Primary HPV testing for high-risk HPV is defined as a stand-alone cervical cancer screening test, without concurrent cytology. Based on the results, it may be followed by cytology for triage of abnormal results (Figure 1). The Cobas HPV DNA test is the only test approved by the U.S. Food and Drug Administration for primary HPV testing. Primary HPV testing should begin three years after the last negative cytology result. It should not be performed more often than every three years or before 25 years of age. In the case of a 24-year-old woman with a negative first cytology result at 21 years of age, cytology alone is recommended because primary HPV testing before 25 years of age is not recommended.

‡—Women younger than 21 years should not be screened for cervical cancer regardless of age at sexual initiation or other behavior-related risk factors. Cervical cancer is rare in women younger than 21 years (0.1% of all cervical cancer cases), but cervical dysplasia is not (in a study of 10,900 Papanicolaou tests performed in females 12 to 18 years of age, 5.7% showed low-grade squamous intraepithelial lesions and 0.7% showed high-grade squamous intraepithelial lesions).<sup>21</sup> This is because most high-risk HPV infections in this age group are transient because of effective immune response that clears

Primary HPV screening should not be performed in women younger than 25 years or older than 65 years, or in women who are immunocompromised.<sup>4</sup> Rescreening after a negative primary HPV test result should occur no earlier than three years later, and patients with positive results should be tested for specific HPV genotype. If testing is negative for HPV types 16 and 18 but positive for other high-risk genotypes, then cytology should be performed. If cytology

results are negative, then follow-up testing should be performed in 12 months (Figure 1).<sup>15</sup> The type of follow-up testing to perform is not specified in the interim guideline, but the American College of Obstetricians and Gynecologists recommends cotesting.<sup>4,15</sup>

It is likely that primary HPV testing in 25- to 29-year-old women will lead to increased CIN3 detection, but the actual impact on cervical cancer prevention in this age group

**ACOG 2016<sup>4</sup>****ASCCP and SGO 2015<sup>15</sup>: interim guidance on primary testing† for high-risk HPV infection**

Screening is not recommended	Screening is not recommended
Cytology alone every three years	Primary HPV testing every three years (alternative to cytology alone or cotesting) for women 25 years and older; not recommended in women 21 to 25 years of age
Cotesting every five years (preferred) Cytology alone every three years (acceptable)	Primary HPV testing every three years (alternative to cotesting or cytology alone)
Screening is not recommended in women older than 65 years with an adequate history of negative screening results	Not addressed
Annual screening is not recommended Patients should be counseled that annual well-woman visits are recommended even if cervical cancer screening is not performed at each visit	Not addressed

the infection in an average of eight months or decreases the viral load to undetectable levels in an average of eight to 24 months in 85% to 90% of women younger than 21 years.<sup>4</sup> Studies in the United States and United Kingdom have shown that screening women younger than 21 years does not decrease the rate of cervical cancer in this age group, and instead increases harms from unnecessary diagnostic procedures.<sup>4</sup>

§—There is insufficient evidence to support screening intervals longer than five years in women 30 to 65 years of age, even with a history of negative cytology results.

||—Adequate history of negative screening results is defined as three consecutive negative cytology results or two consecutive negative cotest results within the previous 10 years, with the most recent test performed within the past five years. For women older than 65 years who do not meet these criteria, it is recommended that routine screening (cytology alone every three years or cotesting every five years) be continued for at least 20 years. Women older than 65 years with adequate prior negative screening and a new sex partner do not need to continue or resume cervical cancer screening.

Information from references 4, and 15 through 21.

needs further investigation.<sup>15</sup> Some believe that the harms of excessive diagnostic testing will outweigh the benefits.<sup>23</sup> Primary HPV testing is a rapidly evolving area of preventive medicine. Randomized controlled trials are global and ongoing, and include studies on patient-collected HPV samples.<sup>23-29</sup> Primary polymerase chain reaction–based HPV testing via self-sampling has similar sensitivity to that of an in-office collection method, with reportedly

ing, out-of-pocket expenses, and invasive procedures such as colposcopy with cervical biopsy.<sup>18</sup>

The harms of diagnostic testing with colposcopy or endocervical curettage include bleeding, pain, infection, and failure to diagnose from inadequate sampling.<sup>18</sup> Short-term risks of treatment methods include bleeding, pain, and infection. Long-term risks of treatment include subsequent preterm delivery and neonatal mortality because of severe

wider acceptability and positive feedback, especially in underscreened and unscreened patient populations.<sup>24-29</sup>

### Weighing the Benefits and Harms of Screening

The primary goal of cervical cancer screening is to decrease mortality by detecting precancerous lesions and intervening to prevent the progression to cervical cancer. It is important to recognize that the risk of HPV infection is highest among those who are newly sexually active, and that the risk decreases with age.<sup>20</sup> The peak incidence of high-risk HPV infection is in teenagers and in women in their early 20s.<sup>4</sup> The progression from persistent high-risk HPV infection to invasive cervical disease takes an average of 10 to 20 years (*Figure 2*).<sup>30</sup> Because of this slow oncogenesis, persistent high-risk HPV infections that manifest as abnormalities of the cervix can be detected early, resulting in less-invasive treatments and overall fewer adverse outcomes.<sup>18</sup>

The optimal cervical cancer screening program maximizes the benefit to women and minimizes harms and the costs of screening. Harms are related to both screening tests and the procedures required for diagnosis, management, and follow-up of patients with abnormal screening results.<sup>20</sup> Screening tests and subsequent diagnosis and management can lead to psychological harms such as distress and anxiety.<sup>18,20</sup> The pelvic examination and Pap test can cause mild bleeding and cramping in some women. Additionally, inadequate sampling may necessitate repeat procedures. Abnormal screening test results can lead to more frequent test-

TABLE 3

## Other Cervical Cancer Screening Recommendations

Patient factors	Recommendations			
	ACS, ASCCP, and ASCP 2012 <sup>16</sup>	USPSTF and AAFP 2012 <sup>18,19</sup>	ACP 2015 <sup>20</sup>	ACOG 2016 <sup>4</sup>
Immunosuppression* (includes solid organ transplant recipients; those with autoimmune conditions or HIV infection; and those taking immunosuppressive medications; does not include otherwise healthy pregnant women†)	Not addressed; recommends referring to CDC/NIH/IDSA guidelines <sup>22</sup>	Not addressed; recommends referring to CDC/NIH/IDSA guidelines <sup>22</sup>	Not addressed	Initiate screening within one year of onset of sexual activity or, if already sexually active, within the first year after HIV diagnosis but no later than 21 years of age; continue screening throughout the woman's lifetime—annually until sufficient negative screenings are achieved, then every three years; screening is not stopped at 65 years of age and cotesting is not recommended for women younger than 30 years
Total hysterectomy (with removal of the cervix) unrelated to cancer‡	Screening should be stopped	Screening should be stopped	Screening should be stopped	Screening should be stopped
Total hysterectomy (with removal of the cervix) related to cancer	Continue screening for 20 years after hysterectomy with cotesting every five years (preferred) or cytology alone every three years (acceptable)	Not addressed	Not addressed	Continue to screen for 20 years after hysterectomy with cytology every three years§
Received human papillomavirus vaccine	Follow age-specific recommendations	Follow age-specific recommendations	Follow age-specific recommendations	Follow age-specific recommendations

AAFP = American Academy of Family Physicians; ACOG = American College of Obstetricians and Gynecologists; ACP = American College of Physicians; ACS = American Cancer Society; ASCCP = American Society for Colposcopy and Cervical Pathology; ASCP = American Society for Clinical Pathology; CDC = Centers for Disease Control and Prevention; CIN = cervical intraepithelial neoplasia; HIV = human immunodeficiency virus; IDSA = Infectious Diseases Society of America; NIH = National Institutes of Health; USPSTF = U.S. Preventive Services Task Force.

\*—There are limited data and no consensus regarding how to routinely screen women who are immunocompromised because of a condition other than HIV. Recommendations have been extrapolated from data in women with HIV infection. Annual cytology beginning at 21 years of age traditionally has been performed.

†—Pregnant women should continue to be screened using age-specific recommendations.

‡—Applies to women without a cervix and without a history of CIN2 or a more severe diagnosis in the past 20 years or cervical cancer ever.

§—Women should continue to be screened if they have had a total hysterectomy and have a history of CIN2 or higher in the previous 20 years or cervical cancer ever. Continued screening for 20 years is recommended in women who still have a cervix and a history of CIN2 or higher. Therefore, screening with cytology alone every three years for 20 years after initial posttreatment surveillance for women with a hysterectomy is reasonable per ACOG.

||—The possibility that vaccination might reduce the need for screening has not yet been established.

Information from references 4, 16, 18 through 20, and 22.

prematurity.<sup>20</sup> Overdiagnosis and overtreatment are common; the treatment threshold in the United States is CIN2, and about 40% of CIN2 lesions regress over six months without intervention.<sup>20</sup>

To reduce harms from cervical cancer screening, guidelines recommend against screening women before 21 years of age and in patients who have had a hysterectomy for reasons unrelated to cancer.<sup>4,16,18,20</sup> Screening should be stopped after 65 years of age in women with an adequate history of negative

screening results.<sup>16,20</sup> Annual screening is not recommended for average-risk women of any age; screening too frequently has been proven to have greater harms than benefits.<sup>4,16,18,20</sup>

### Prevention

Preventing high-risk HPV infection is the key to the prevention of cervical dysplasia and cancer. Barrier contraceptives, such as condoms, are only about 70% effective at preventing HPV transmission.<sup>9</sup> In 2016, the Centers for Disease Control

## CERVICAL CANCER SCREENING

and Prevention changed the recommendations for HPV vaccination to include vaccinating boys and girls before 15 years of age, and as early as nine years of age.<sup>31</sup> A two-dose series is used when initiated before 15 years of age, whereas

a three-dose series is required if initiated at 15 years or older or if the individual is immunocompromised. Vaccination is recommended through 26 years of age for females and 21 years of age for males.<sup>31</sup>


Gardasil-9 (9-valent) is the only FDA-approved HPV vaccine (*eTable A*). If Cervarix (bivalent, no longer available in the United States) or Gardasil (quadrivalent, no longer available in the United States) has already been given, there is no evidence that the patient should be revaccinated using Gardasil-9. Additionally, the HPV vaccination series should be finished with whichever vaccine type is available.<sup>4</sup> Because long-term effectiveness of the vaccine is unknown, all patients with a cervix should undergo age-based cervical cancer screening regardless of vaccination status.<sup>4</sup>

**This article** updates a previous article on this topic by Nuovo, et al.<sup>32</sup>

**Data Sources:** A PubMed search was conducted using the key terms cervical intraepithelial neoplasia, low-grade squamous intraepithelial lesion, Pap smear, cytology, colposcopy, human papillomavirus, HPV, HPV testing, and HPV vaccination. The search included retrospective studies, prospective studies, meta-analyses, and reviews. Essential Evidence Plus, Google Scholar, the National Institute for Health and Care Excellence guidelines, and the Cochrane database were also searched. Search dates: August 2016, February 2017, May 2017, and October 2017.

**The opinions** and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of Defense, the U.S. Army Medical Department, or the U.S. Army Service at large.

**FIGURE 1**



\*—Type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, or 68.


**Algorithm for primary human papillomavirus (HPV) screening.** If primary HPV testing is used for cervical cancer screening, it is recommended that this algorithm be used for management of positive results.

Adapted with permission from Huh WK, Ault KA, Chelmos D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. *Gynecol Oncol.* 2015; 136(2):181.

### The Authors

**CAITLYN M. RERUCHA, MD, FAAFP**, is an assistant professor in the Department of Family Medicine at the Uniformed Services University of the Health Sciences, Bethesda, Md. She is also a clinical assistant professor in the Department of Family

**FIGURE 2**



**Natural history of high-risk cervical human papillomavirus (HPV) infection.** Cervical carcinogenesis starts with sexual transmission of high-risk HPV (infection is transient [90% of cases] or persistent [10%]). High-risk cervical HPV infections are considered persistent if cervical abnormalities or HPV type 16 or 18 is present for more than two years. Persistent infections can progress to invasive cervical cancers if precancerous lesions are not identified and treated.

Adapted with permission from Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. *J Natl Cancer Inst Monogr.* 2003;(31):15.

## CERVICAL CANCER SCREENING

Medicine at Texas A&M College of Medicine, Temple, and is a faculty member in the Family Medicine Residency Program at Carl R. Darnall Army Medical Center, Fort Hood, Tex.

**REBECCA J. CARO, DO**, is an assistant professor in the Department of Family Medicine at the Uniformed Services University of the Health Sciences and a staff physician at Bassett Army Community Hospital, Fort Wainwright, Alaska. At the time this article was written, she was an obstetrics fellow in the Department of Family Medicine at Carl R. Darnall Army Medical Center.

**VERNON L. WHEELER, MD, FAAP**, is an assistant professor in the Department of Family Medicine at the Uniformed Services University of the Health Sciences. He is also a clinical assistant professor in the Department of Family Medicine at Texas A&M College of Medicine and a faculty member in the Family Medicine Obstetrics Fellowship Program at Carl R. Darnall Army Medical Center Family Medicine Residency.

Address correspondence to Caitlyn M. Rerucha, MD, Carl R. Darnall Army Medical Center, 36000 Darnall Loop, Fort Hood, TX 76544 (e-mail: cmreruchamd@gmail.com). Reprints are not available from the authors.

### References

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide. *Int J Cancer*. 2015;136(5):E359-E386.
2. Martin-Hirsch PL, Wood NJ. Cervical cancer. *BMJ Clin Evid*. 2011. <http://clinicalevidence.bmj.com/x/systematic-review/0818/overview.html>. Accessed February 20, 2017.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. *CA Cancer J Clin*. 2017;67(1):7-30.
4. Committee on Practice Bulletins—Gynecology. Practice bulletin no. 168: cervical cancer screening and prevention. *Obstet Gynecol*. 2016;128(4):e111-e130.
5. National Cancer Institute. SEER cancer statistics review, 1975-2014. [http://seer.cancer.gov/csr/1975\\_2013/](http://seer.cancer.gov/csr/1975_2013/). April 2016. Accessed October 31, 2017.
6. Sabatino SA, White MC, Thompson TD, et al. Cancer screening test use—United States, 2013. *MMWR Morb Mortal Wkly Rep*. 2015;64(17):464-468.
7. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol*. 1999;189(1):12-19.
8. National Cancer Institute. HPV and cancer. <https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-fact-sheet#q1>. Accessed February 18, 2017.
9. Juckett G, Hartman-Adams H. Human papillomavirus: clinical manifestations and prevention. *Am Fam Physician*. 2010;82(10):1209-1213.
10. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. *J Natl Cancer Inst*. 2008;100(7):513-517.
11. Singh VB, Gupta N, Nijhawan R, et al. Liquid-based cytology versus conventional cytology for evaluation of cervical Pap smears. *Indian J Pathol Microbiol*. 2015;58(1):17-21.
12. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. *Obstet Gynecol*. 2009;113(1):18-25.
13. Arbyn M, Bergeron C, Klinkhamer P, et al. Liquid compared with conventional cervical cytology. *Obstet Gynecol*. 2008;111(1):167-177.
14. Vesco KK, Whitlock EP, Eder M, et al. Screening for cervical cancer: a systematic evidence review for the U.S. Preventive Services Task Force. May 2011. <https://www.uspreventiveservicestaskforce.org/Home/GetFile/1/262/cervcancer/pdf>. Accessed February 20, 2017.
15. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. *Gynecol Oncol*. 2015;136(2):178-182.
16. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. *CA Cancer J Clin*. 2012;62(3):147-172.
17. American Academy of Family Physicians. Choosing Wisely. Screening for cervical cancer in women younger than 30 years of age. <http://www.aafp.org/patient-care/clinical-recommendations/all/cw-cervical-cancer.html>. Accessed June 18, 2017.
18. U.S. Preventive Services Task Force. Screening for cervical cancer. 2012. <https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/cervical-cancer-screening>. Accessed September 17, 2017.
19. American Academy of Family Physicians. Clinical preventive service recommendations. Cervical cancer. <https://www.aafp.org/patient-care/clinical-recommendations/all/cervical-cancer.html>. Accessed October 31, 2017.
20. Sawaya GF, Kulasingam S, Denberg TD, Qaseem A; American College of Physicians. Cervical cancer screening in average-risk women. *Ann Intern Med*. 2015;162(12):851-859.
21. Wright JD, Davila RM, Pinto KR, et al. Cervical dysplasia in adolescents. *Obstet Gynecol*. 2005;106(1):115-120.
22. Centers for Disease Control and Prevention, National Institutes of Health, Infectious Diseases Society of America. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. [http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult\\_o.pdf](http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_o.pdf). Accessed January 30, 2018.
23. Wright TC, Stoler MH, Behrens CM, et al. Primary cervical cancer screening with human papillomavirus. *Gynecol Oncol*. 2015;136(2):189-197.
24. Kitchener HC, Canfell K, Gilham C, et al. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical cancer screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. *Health Technol Assess*. 2014;18(23):1-196.
25. Passamonti B, Gustinucci D, Giorgi Rossi P, et al. Cervical human papilloma virus (HPV) DNA primary screening test. *J Med Screen*. 2017;24(3):153-162.
26. Petrelli A, Di Napoli A, Giorgi Rossi P, et al. Prevalence of primary HPV in Djibouti: feasibility of screening for early diagnosis of squamous intraepithelial lesions. *J Low Genit Tract Dis*. 2016;20(4):321-326.
27. Arbyn M, Verdoodt F, Snijders PJ, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. *Lancet Oncol*. 2014;15(2):172-183.
28. Nelson EJ, Maynard BR, Loux T, et al. The acceptability of self-sampled screening for HPV DNA. *Sex Transm Infect*. 2017;93(1):56-61.
29. Wong EL, Cheung AW, Huang F, Chor JS. Can human papillomavirus DNA self-sampling be an acceptable and reliable option for cervical cancer screening in female sex workers? [published ahead of print January 20, 2017]. *Cancer Nurs*. <https://insights.ovid.com/pubmed?pmid=28114260> [password required]. Accessed June 9, 2017.
30. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. *J Natl Cancer Inst Monogr*. 2003; (31):14-19.
31. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination—updated recommendations of the Advisory Committee on Immunization Practices. *MMWR Morb Mortal Wkly Rep*. 2016;65(49):1405-1408.
32. Nuovo J, Melnikow J, Howell LP. New tests for cervical cancer screening. *Am Fam Physician*. 2001;64(5):780-786.

## CERVICAL CANCER SCREENING

**eTABLE A**

### Comparison of HPV Vaccines

Vaccine	HPV genotypes covered	Indications	Age-based recommendations
Gardasil-9	6, 11, 16, 18, 31, 33, 45, 52, and 58	Prevent cervical cancer in females Prevent genital warts in all individuals	<p><b>Females</b></p> <p>Give at 11 to 12 years; may be given as early as nine years</p> <p>Two-dose series if started &lt; 15 years</p> <p>Three-dose series if started ≥ 15 years or if the patient is immunocompromised*</p> <p>Vaccinate through 26 years</p> <p><b>Males</b></p> <p>Give at 11 to 12 years; may be given as early as nine years</p> <p>Two-dose series if started &lt; 15 years</p> <p>Three-dose series if started ≥ 15 years or if the patient is immunocompromised*</p> <p>Vaccinate through 21 years; may vaccinate through 26 years</p> <p>Men who have sex with men and males who are immunocompromised* should be vaccinated through 26 years</p>
Gardasil (no longer available in the United States)	6, 11, 16, and 18	Prevent cervical, vaginal, and vulvar cancers in females Prevent penile cancer in males Prevent genital warts, oropharyngeal cancer, and anal cancer in all individuals	<p><b>Females</b></p> <p>Give at 11 to 12 years; may be given as early as nine years</p> <p><b>Males</b></p> <p>Give at 11 to 12 years; may be given at nine to 26 years</p>
Cervarix (no longer available in the United States)	16 and 18	Prevent cervical cancer in females	<p><b>Females</b></p> <p>Give at 11 to 12 years; may be given as early as nine years</p>

CIN = cervical intraepithelial neoplasia; HPV = human papillomavirus.

\*—Includes those with human immunodeficiency virus infection, cancer, or autoimmune disease, or those taking immunosuppressant medications. This excludes children with asthma, diabetes mellitus, and other conditions that would not suppress immune response to HPV vaccination.

Information from:

CDC recommendations for HPV vaccine 2-dose schedules. <https://www.cdc.gov/hpv/downloads/hcvg15-ptt-hpv-2dose.pdf>. Accessed June 7, 2017.  
Centers for Disease Control and Prevention. Information for parents. HPV vaccine is safe-(Gardasil). April 8, 2016. <https://www.cdc.gov/vaccinesafety/pdf/data-summary-hpv-gardasil-vaccine-is-safe.pdf>. Accessed June 18, 2017.

Centers for Disease Control and Prevention. Vaccine information statement. HPV (human papillomavirus) vaccine: what you need to know. <https://www.cdc.gov/vaccines/hcp/vis/vis-statements/hpv.pdf>. Accessed June 7, 2017.

Cervarix [package insert]. Research Triangle, N.C.: GlaxoSmithKline Biologicals; 2009. <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186957.htm>. Accessed October 30, 2017.

## CERVICAL CANCER SCREENING

Injection schedule	Effectiveness	Common adverse effects
0, and 6 to 12 months or 0, 2, and 6 months	HPV susceptibility 90% for invasive cervical cancer Up to 93.6% for CIN2 and CIN3 lesions Disease reduction 42.5% for high-grade squamous intraepithelial lesions	Pain, swelling, and redness at injection site (20% to 89%) Headache (11% to 14%) Fever (0.7% to 5%)
0, and 6 to 12 months or 0, 2, and 6 months	HPV susceptibility 100% for external vaginal lesions 98% to 100% for CIN2 or CIN3 lesions Disease reduction 34% for external vaginal lesions 17% to 20% for cervical lesions	Pain, swelling, and redness at injection site (13% to 83%) Headache (12% to 28%) Fever (8% to 13%)
0, 2, and 6 months	HPV susceptibility 98% for CIN2 or CIN3 lesions associated with HPV types 16 and 18 Disease reduction 30% for CIN2 or CIN3 lesions associated with all HPV types	Pain, swelling, and redness at injection site (44% to 91%) Headache (53%) Fever (12%)

*Information from:*

Gardasil [package insert]. Whitehouse Station, N.J.: Merck Sharp & Dohme Corp; 2006. [http://www.merck.com/product/usa/pi\\_circulars/g/gardasil/gardasil\\_pi.pdf](http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf). Accessed June 9, 2017.

Gardasil 9 [package insert]. Whitehouse Station, N.J.: Merck Sharp & Dohme Corp; 2014. <http://www.gardasil9.com>. Accessed June 9, 2017.

Juckett G, Hartman-Adams H. Human papillomavirus: clinical manifestations and prevention. *Am Fam Physician*. 2010;82(10):1209-1213.

Lopalco PL. Spotlight on the 9-valent HPV vaccine. *Drug Des Devel Ther*. 2016;11:35-44.

Markowitz L; Advisory Committee on Immunization Practices. 2-dose HPV vaccination schedules: review of evidence. October 19, 2016. <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2016-10/hpv-02-markowitz-oct-2016.pdf>. Accessed June 18, 2017.

Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination—updated recommendations of the Advisory Committee on Immunization Practices. *MMWR Morb Mortal Wkly Rep*. 2016;65(49):1405-1408.

Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. *Infect Agent Cancer*. 2012;7(1):38.

Copyright of American Family Physician is the property of American Academy of Family Physicians and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.